Published in Breast Cancer Res Treat on December 01, 2002
Genetic regulation of MUC1 alternative splicing in human tissues. Br J Cancer (2008) 1.14
MUC1 as a Putative Prognostic Marker for Prostate Cancer. Biomark Insights (2008) 0.82
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med (2007) 12.17
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSα. Cell (2013) 2.87
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
A Gja1 missense mutation in a mouse model of oculodentodigital dysplasia. Development (2005) 1.93
Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncol (2011) 1.78
Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev (2011) 1.74
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66
Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res (2008) 1.60
A prognostic gene expression index in ovarian cancer - validation across different independent data sets. J Pathol (2009) 1.55
Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer. Breast Cancer Res Treat (2006) 1.46
Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol (2006) 1.42
To butterfly or to needle: the pilot phase. Ann Intern Med (2004) 1.40
Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res (2004) 1.36
Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev (2010) 1.34
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer (2009) 1.33
Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival. Cancer (2005) 1.27
Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res (2004) 1.26
Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res (2007) 1.26
Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast cancer. Clin Cancer Res (2006) 1.24
Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women. Clin Cancer Res (2005) 1.23
The neuronal guidance cue Slit2 induces targeted migration and may play a role in brain metastasis of breast cancer cells. Breast Cancer Res Treat (2007) 1.23
Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Oncotarget (2014) 1.18
Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res (2005) 1.13
Characterization of benign and malignant breast lesions with computed tomography laser mammography (CTLM): initial experience. Invest Radiol (2005) 1.10
Effect of carcinogenic acrolein on DNA repair and mutagenic susceptibility. J Biol Chem (2012) 1.07
CXCR4 is expressed in ductal carcinoma in situ of the breast and in atypical ductal hyperplasia. Breast Cancer Res Treat (2004) 1.06
Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res (2005) 1.05
Identification of genes associated with the invasive status of human mammary carcinoma cell lines by transcriptional profiling. Tumour Biol (2003) 1.04
ODDD-linked Cx43 mutants reduce endogenous Cx43 expression and function in osteoblasts and inhibit late stage differentiation. J Bone Miner Res (2008) 1.03
An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res (2003) 1.02
The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells. Breast Cancer Res Treat (2010) 1.01
A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression. Mol Cancer Ther (2011) 1.01
Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women. Cancer (2004) 0.99
Circulating tumor cells in metastatic colorectal cancer: efficacy and feasibility of different enrichment methods. Cancer Lett (2010) 0.99
Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. Clin Cancer Res (2002) 0.99
Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol (2003) 0.99
Methylation status of TUSC3 is a prognostic factor in ovarian cancer. Cancer (2012) 0.99
Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport. Biomed Pharmacother (2011) 0.99
Identification of L1CAM, Jagged2 and Neuromedin U as ovarian cancer-associated antigens. Oncol Rep (2005) 0.98
Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. Int J Gynecol Cancer (2012) 0.98
Antiestrogens and their therapeutic applications in breast cancer and other diseases. Annu Rev Med (2011) 0.98
Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: proof of concept. Cytometry B Clin Cytom (2010) 0.98
Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response. Oncol Rep (2004) 0.97
Oncogenic BARD1 isoforms expressed in gynecological cancers. Cancer Res (2007) 0.95
Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium. Gynecol Oncol (2012) 0.95
Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization. J Mol Diagn (2009) 0.95
Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD Consortium. Cancer Sci (2012) 0.94
PROGINS receptor gene polymorphism is associated with endometriosis. Fertil Steril (2002) 0.94
Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer (2010) 0.93
Co-regulated gene expression by oestrogen receptor α and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cells. Nucleic Acids Res (2013) 0.93
Expression profiling of mammary carcinoma cell lines: correlation of in vitro invasiveness with expression of CD24. Tumour Biol (2002) 0.93
HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer. Oncol Rep (2005) 0.93
Phytoestrogens in clinical practice: a review of the literature. Fertil Steril (2007) 0.93
Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines. Breast Cancer Res Treat (2003) 0.92
Expression of MUC1 splice variants in benign and malignant ovarian tumours. Int J Cancer (2002) 0.92
A common interleukin-6 gene promoter polymorphism influences the clinical characteristics of women with polycystic ovary syndrome. Fertil Steril (2004) 0.91
Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. Anticancer Res (2003) 0.91
A male sterility-associated cytotoxic protein ORF288 in Brassica juncea causes aborted pollen development. J Exp Bot (2011) 0.90
Genotype distribution of estrogen receptor-alpha, catechol-O-methyltransferase, and cytochrome P450 17 gene polymorphisms in Caucasian women with uterine leiomyomas. Fertil Steril (2006) 0.89
Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD. Int J Gynecol Cancer (2013) 0.89
A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium. BMC Cancer (2013) 0.89
Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Gynecol Oncol (2005) 0.89
Expression of estrogen receptor beta isoforms in human breast cancer tissues and cell lines. Breast Cancer Res Treat (2002) 0.89
Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium. J Ovarian Res (2013) 0.89
Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium. BMC Cancer (2013) 0.89
Circulating tumor cells in small cell lung cancer: ex vivo expansion. Lung (2015) 0.89
Loss of the oligosaccharyl transferase subunit TUSC3 promotes proliferation and migration of ovarian cancer cells. Int J Oncol (2013) 0.89
Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortium. Mol Cancer (2012) 0.88
Polymorphisms of the endothelial nitric oxide synthase gene in ovarian cancer. Gynecol Oncol (2002) 0.88
Human progesterone receptor gene polymorphism PROGINS and risk for breast cancer in Austrian women. Breast Cancer Res Treat (2002) 0.88